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Prevention or reduction of ischemia/ reperfusion injury would be of great benefit in organ
transplantation. Here we briefly report preliminary studies evaluating a combined protocol
using SRI 63-441 (Sandoz Pharmaceuticals, Raritan, NJ), a potent platelet-activating factor
receptor antagonist,1 and superoxide dismutase (SOD), an oxygen free radical scavenger, in
an attempt to reduce ischemic injury to the liver.
MATERIALS AND METHODS
Male Lewis rats (250 to 300 g) were used as liver donors, and retired breeders were used as
blood donors. Methoxyflurane-anesthetized rats received 300 U of heparin intravenously
(IV) five minutes prior to cannuiation of the bile duct and induction of total hepatic
ischemia. After 90 minutes of ischemia, the portal vein was cannulated and the liver
harvested. Group 1, no drug treatment (N − 11); group 2, 12 mg/kg of SOD was added to
the flush at harvest and 8 mg/kg of SOD was added to the perfusate at zero, five, and ten
minutes of perfusion (N − 4); group 3, rats received 12 mg/kg of SOD IV at the time of
heparinization and 12 mg/kg of SOD was added to the flush at harvest (N − 4); group 4, rats
received 12 mg/kg of SOD IV at the time of heparinization, 12 mg/kg SOD was added to the
flush at harvest, and 8 mg/kg of SOD was added to the perfusate at zero, five, and ten
minutes of perfusion (N − 4); group 5, rats received 20 mg/kg of SRI 63-441 at the time of
heparinization, 6.5 mg/kg of SOD was added to the flush at harvest, and 6.5 mg/kg of SOD
was added to the perfusate at zero minutes of perfusion (N − 6). Upon harvest, the liver was
flushed with 60 mL cooled, heparinized (10 U/mL) Ringer’s lactate solution (4°C), placed
on a perfusion apparatus,2 and perfused with a warm, oxygenated (pO2, 500 torr), dilute
sanguinous (hct, 25; diluent, Krebs bicarbonate buffer) solution at 37°C, pH 7.4 for 90
minutes. Bile production and perfusate SGOT and SGPT levels were measured every 30
minutes. Results are expressed as mean ± SEM and compared using an independent
Student’s t test.
RESULTS
The three groups using SOD alone (groups 2, 3, and 4) all show an increase in bile
production and a decrease in perfusate transaminases when compared to controls (group 1)
(Table 1). Only in group 2 was a significant difference seen in all three parameters measured
(P < .05). There was a significant increase in bile production in group 5 compared to group 1
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(P <.005); however, there was no significant difference between transaminase levels of the
two groups.
DISCUSSION AND CONCLUSIONS
It has recently been suggested that platelet activating factor (PAF) may be a central mediator
of the microcirculatory failure that ensues following ischemic organ injury. PAF is released
from a number of cells and plays a significant role in almost every aspect of the
inflammatory response.3 SRI 63-441 is the most potent PAF receptor antagonist developed
to date. In our previous study, there was a significant increase in bile production and
decrease in perfusate transaminases in animals pretreated with 20 mg/kg of SRI 63-441 prior
to induction of ischemia compared with controls.4 It was anticipated that the addition of a
second agent, which acted through a different mechanism, might further improve
postischemic hepatic function. SOD has been shown to be protective in kidneys subjected to
warm ischemia.5 The decision to add SOD was based on the preliminary results in groups 2,
3, and 4. A lesser dose of SOD was added in the combined study because earlier
experiments (not reported) at the higher dosage did not show an increase in bile production
and there was some concern of toxicity. The preliminary studies with SOD indicated that, as
expected, SOD must be present at the time of reperfusion to exert a beneficial effect. The
addition of SOD to SRI 63-441 pretreatment did not result in an improvement over SRI
63-441 pretreatment alone. In fact, at this time, the results are equivocal with an
improvement in bile production, but none in perfusate transaminases. The complexity and
multiplicity of cascades involved in the mediation of ischemia/reperfusion injury make it
highly likely that effective pharmacologic modulation of the injury, leading to prolongation
of organ preservation, will involve a poly-pharmacy approach. The ultimate “cocktail”
would contain several agents that act at different critical points along the multiple pathways.
It is not unexpected, as in the study reported here, that agents anticipated to behave
synergistically could upset the fine balance in the cell’s homeostatic mechanisms and invoke
a detrimental response.
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